Your shopping cart is currently empty

Dot1l-in-2 is an effective, selective and oral bioutilization inhibitor of histone methyltransferase Dot1L, with IC50 and Ki of 0.4 nM and 0.08 nM, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,670 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $2,180 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,800 | 6-8 weeks | 6-8 weeks |
| Description | Dot1l-in-2 is an effective, selective and oral bioutilization inhibitor of histone methyltransferase Dot1L, with IC50 and Ki of 0.4 nM and 0.08 nM, respectively. |
| Targets&IC50 | DOT1L:(ki)0.08 nM , DOT1L:0.4 nM |
| In vitro | Dot1l-in-2 is an effective and selective Dot1L inhibitor with IC50 and Ki of 0.4 nM and 0.08 nM, respectively.Dot1l-in-2 effectively inhibits H3K79 dimethylation (IC50, 16 nM) and blocks the activity of the HoxA9 promoter (IC50, 340 nM) IN the cellular system.Dot1l-in-2 also significantly inhibited the proliferation of human mll-recombinant leukemia cell line mv4-11 carrying carcinogenic mll-af4 fusion (IC50, 128nm). |
| Molecular Weight | 476.53 |
| Formula | C27H24N8O |
| Cas No. | 1940206-71-2 |
| Smiles | CC=1N(C=2C(C1)=CC=C(NC=3N=C(NC)C=CN3)C2)C4=C(OC=5C=C6C(=NC5)N(C)C=N6)C=CC=C4 |
| Relative Density. | 1.36 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.